Details

Last Funding Type

Post-IPO Debt

Last Funding Money Raised

$5M

Industries

Biotechnology,Health Care,Therapeutics

Founded date

Jan 1, 1991

Number Of Employee

251 - 500

Operating Status

Active

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.